ID   DPX2
AC   CVCL_UK01
SY   DPX-2
DR   CLO; CLO_0037254
DR   Wikidata; Q93531270
RX   PubMed=15466163;
RX   PubMed=16146350;
RX   PubMed=22912432;
WW   https://www.promegaconnections.com/tag/dpx2-cells/
CC   Population: Caucasian.
CC   Biotechnology: Used in cell-based assays for a parallel assessment of CYP3A4 induction, metabolism and inhibition at the cellular level.
CC   Characteristics: The luciferase reporter gene is under the control of CYP3A4 response elements (proximal promoter and distal xenobiotic-responsive enhancer module).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 7968; NR1I2.
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 20-05-21; Version: 7
//
RX   PubMed=15466163; DOI=10.1124/dmd.104.001594;
RA   Yueh M.-F., Kawahara M., Raucy J.L.;
RT   "High volume bioassays to assess CYP3A4-mediated drug interactions:
RT   induction and inhibition in a single cell line.";
RL   Drug Metab. Dispos. 33:38-48(2005).
//
RX   PubMed=22912432; DOI=10.1124/dmd.112.047456;
RA   Fahmi O.A., Raucy J.L., Ponce E., Hassanali S., Lasker J.M.;
RT   "Utility of DPX2 cells for predicting CYP3A induction-mediated
RT   drug-drug interactions and associated structure-activity
RT   relationships.";
RL   Drug Metab. Dispos. 40:2204-2211(2012).
//